Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ILK | Q13418 | 3/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009918 | 0.82 | RAB9A (0.57) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1128092 | 0.79 | NPC1 (0.57) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL827403 | 0.78 | RAB9A (0.67) | KDM4EPKMRAB9ANPC1ALDH1A1 | |
| SCHEMBL4495847 | 0.78 | RAB9A (0.53) | KDM4EPKMRAB9ANPC1ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL28205214 | 0.76 | RAB9A (0.64) | KDM4EPKMRAB9ANPC1ALDH1A1 | |
| Hydrogen Sulfide SCHEMBL16859912 | 0.76 | RAB9A (0.64) | KDM4EPKMRAB9ANPC1ALDH1A1 | |
| Methane SCHEMBL28056221 | 0.76 | RAB9A (0.64) | KDM4EPKMRAB9ANPC1ALDH1A1 | |
| SCHEMBL12861180 | 0.73 | RAB9A (0.59) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2139236 | 0.73 | KDM4E (0.64) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29829782 | 0.73 | KDM4E (0.64) | KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2015-04-30 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937041-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2658859-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ABBVIE INC. | 2012-07-05 | — | — | US | disclosed |
| WO-2012092409-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARARMACEUTICALS, INC (US) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119319-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | KDM4E 3420/4885PKM 2102/4885RAB9A 2511/4885 |
| US-20120172291-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | KDM4E 3420/4885PKM 2102/4885RAB9A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.